Market Research Logo

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Summary


Colorectal cancer (CRC) originates in either the colon or the rectum. It is one of the most common types of cancers, and is the third most common cancer among men and the second most common in women (ACS, 2017a; Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind those of lung, liver, and stomach cancer. It’s global age-standardized mortality rates are 20.6 and 14.3 deaths per 100,000 population for men and women, respectively (Ferlay et al., 2016). Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma and squamous cell carcinoma (Kim et al., 2016).

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000 (Chen et al., 2016).

In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases (NCC, 2016a). CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men (Watanabe et al., 2015). In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country (NCC, 2016b).

In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options (AGCA, 2017). The incidence of CRC is still several folds lower in India than in most developing and developed countries (Mallath, 2014). However, the country has witnessed a steady increase in numbers in line with its increasing urbanization.

The report “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market” analyzes the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Furthermore, this report helps to understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Companies mentioned in this report: Merck & Co., Roche, Sumitomo Dainippon Pharma, Array BioPharma, AB Science, Hutchison MediPharma, Jiangsu Chia-Tai Tianqing, Suzhou Zelgen

Biopharmaceuticals

Scope


The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

  • How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?
The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
  • What implications will the increased focus on targeted therapies have on the future of CRC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, obesity and lifestyle influence the market?
Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?
Reasons to buy
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
    • Epidemiology
      • Table Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013
    • Symptoms
      • Table CRC Therapeutics Market, Symptoms of CRC
    • Etiology and Pathophysiology
      • Etiology
      • Pathophysiology
      • Biomarkers/Targets of Interest
    • Diagnosis
      • Digital Rectal Examination
      • Fecal Occult Blood Test
      • Flexible Sigmoidoscopy
      • Colonoscopy
      • Virtual Colonoscopy
      • Double Contrast Barium Enema
    • Disease Stages
      • Table CRC Therapeutics Market, Stage Definitions for CRC
    • Prognosis
      • Table CRC Therapeutics Market, Prognosis for CRC
    • Treatment Guidelines and Options
      • Surgery and Radiation Therapy
        • Table CRC Therapeutics, Surgical Options for CRC
      • Chemotherapy
      • Targeted Therapies
      • Resistance to Pharmacological Therapies
      • Treatment Algorithm
        • Table Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC
  • Marketed Products
    • Overview
    • Chemotherapies
      • Lonsurf (Trifluridine plus Tipiracil) –Taiho Pharma
      • TS-1 (Tegafur plus Gimeracil plus Oteracil) –Taiho Pharma
      • UFT (tegafur plus uracil) –Merck KGaA
    • Epidermal Growth Factor Receptor Targeted Therapies
      • Erbitux (cetuximab) –Eli Lilly/Merck KGaA
      • Vectibix (panitumumab) –Amgen/Takeda
    • Anti-angiogenesis Therapies
      • Avastin (bevacizumab) –Roche
      • Cyramza (ramucirumab) –Eli Lilly
      • Zaltrap (Ziv-Aflibercept) –Sanofi/Regeneron
    • Kinase Inhibitors
      • Stivarga (regorafenib) –Bayer/Onyx
    • Comparative Efficacy and Safety of Marketed Products
      • Table Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
  • Pipeline Analysis
    • Overview
    • Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
      • Table Figure 4: CRC Therapeutics Market, Global, Pipeline, 2017
    • Pipeline by Molecular Target
      • Table Figure 5: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2017
      • Table Figure 6: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017
    • Promising Pipeline Candidates
      • Keytruda (pembrolizumab) –Merck & Co.
        • Table Figure 7: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2021–2023
      • Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) –Roche
        • Table Figure 8: CRC Therapeutics Market, APAC, Tecentriq plus Cotellic Forecast ($m), 2021–2023
      • Napabucasin (BBI-608) –Sumitomo Dainippon Pharma
        • Table Figure 9: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2021–2023
      • Encorafenib plus binimetinib (LGX-818/MEK-162) –Array BioPharma
        • Table Figure 10: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021–2023
      • Masitinib – AB Science
        • Table Figure 11: CRC Therapeutics Market, APAC, Masitinib Forecast ($m), 2019–2023
      • Fruquintinib (HMPL-013) –Hutchison MediPharma
        • Table Figure 12: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018–2023
      • Famitinib (SHR-1020) –Jiangsu Hengrui Medicine
        • Table Figure 13: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2019–2023
      • Anlotinib (AL-3818) –Jiangsu Chia-Tai Tianqing
        • Table Figure 14: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020–2023
      • Donafenib (CM-4307) –Suzhou Zelgen Biopharmaceuticals
        • Table Figure 15: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021–2023
    • Comparative Efficacy and Safety of Pipeline Products
      • Table Figure 16: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 17: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline First-Line Products, 2017
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 18: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2016
      • Failure Rate by Phase and Molecule Type
        • Table Figure 19: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016
      • Failure Rate by Phase and Molecular Target
        • Table Figure 20: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016
    • Clinical Trial Size
      • Patient Enrollment per Product by Molecule Type and Stage of Development
        • Table Figure 21: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Product by Molecular Target and Stage of Development
        • Table Figure 22: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2016
      • Patient Enrollment per Trial by Molecule Type and Stage of Development
        • Table Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Trial by Molecular Target and Stage of Development
        • Table Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006–2016
    • Clinical Trial Duration
      • Trial Duration by Molecule Type and Stage of Development
        • Table Figure 25: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2016
      • Trial Duration by Molecular Target and Stage of Development
        • Table Figure 26: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006–2016
    • Summary of Clinical Trial Metrics
      • Table Figure 27: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 28: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-scenario Forecast
    • Overview
    • Asia-Pacific Market
      • Table Figure 29: CRC Therapeutics Market, APAC, Treatment Patterns (`000), 2016–2023
      • Table Figure 30: CRC Therapeutics Market, APAC, Market Size ($bn), 2016–2023
    • India
      • Treatment Usage Patterns
        • Table Figure 31: CRC Therapeutics Market, India, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 32: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 33: CRC Therapeutics Market, India, Market Size ($m), 2016–2023
    • China
      • Treatment Usage Patterns
        • Table Figure 34: CRC Therapeutics Market, China, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 35: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 36: CRC Therapeutics Market, China, Market Size ($bn), 2016–2023
    • Australia
      • Treatment Usage Patterns
        • Table Figure 37: CRC Therapeutics Market, Australia, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 38: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 39: CRC Therapeutics Market, Australia, Market Size ($m), 2016–2023
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 40: CRC Therapeutics Market, South Korea, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 41: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 42: CRC Therapeutics Market, South Korea, Market Size ($m), 2016–2023
    • Japan
      • Treatment Usage Patterns
        • Table Figure 43: CRC Therapeutics Market, Japan, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 44: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 45: CRC Therapeutics Market, Japan, Market Size ($bn), 2016–2023
  • Drivers and Barriers
    • Drivers
      • Increasing Elderly Population and Incidence of CRC
      • Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate
      • Increase in Mutation Testing to Drive Market Growth
      • Availability of Novel First-, Second- and third-Line Therapy Options in Pipeline
      • Diversified Healthcare Reform to Boost Market Growth
      • Diversified Health Insurance System to Help Nurture Growth
    • Barriers
      • Patent Expiration of Branded Therapies to Affect CRC Market Growth
      • High Prices of Therapeutics to Slow Down Market Growth
      • Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm
      • Lack of Development of Neoadjuvant and Adjuvant Pipeline Products
      • Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
      • Drug Pricing Reforms
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
        • Table Figure 46: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 47: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017
        • Table Figure 49: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2017
        • Table Figure 50: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2017
      • Key Licensing Deals
        • Table CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2006–2017
    • Co-development Deals
      • Deals by Region and Value
        • Table Figure 51: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006–2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 52: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017
        • Table Figure 54: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006–2016
        • Table Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–2016
      • Key Co-development Deals
        • Table CRC Therapeutics Market, Global, Co-development Deals Value, 2006–2016
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
      • Preclinical
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017
      • Investigational New Drug/Clinical Trial Authorization-Filed
        • Table CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2017
      • Phase I
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
      • Phase II
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
      • Phase III
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
      • Pre-registration
        • Table CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017
    • Summary of Multi-scenario Market Forecasts to 2023
      • Asia-Pacific
        • Table CRC Therapeutics Market, APAC, Market Forecast, 2016–2023
      • India
        • Table CRC Therapeutics Market, India, Market Forecast, 2016–2023
      • China
        • Table CRC Therapeutics Market, China, Market Forecast, 2016–2023
      • Australia
        • Table CRC Therapeutics Market, Australia, Market Forecast, 2016–2023
      • South Korea
        • Table CRC Therapeutics Market, South Korea, Market Forecast, 2016–2023
      • Japan
        • Table CRC Therapeutics Market, Japan, Market Forecast, 2016–2023
    • Bibliography
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report